Welcome to our dedicated page for Marimed news (Ticker: MRMD), a resource for investors and traders seeking the latest updates and insights on Marimed stock.
Marimed Inc. (MRMD) operates as a vertically integrated cannabis company with a regulated seed-to-sale approach across multiple states. This page aggregates official press releases and verified news about the company’s cultivation practices, product innovations, and market expansions.
Investors and industry professionals will find timely updates on MRMD’s operational milestones, including regulatory compliance developments, retail dispensary openings, and wholesale distribution partnerships. The curated collection includes earnings reports, leadership announcements, and strategic initiatives shaping the company’s position in the cannabis sector.
Key content categories cover facility certifications, new market entries, product line expansions, and compliance achievements. All materials reflect MRMD’s commitment to operating within strict regulatory frameworks while maintaining product consistency through GMP-certified production processes.
Bookmark this page for direct access to primary-source information about Marimed’s operational and financial developments. Check regularly for updates impacting the company’s performance in evolving cannabis markets.
MariMed, Inc. (CSE: MRMD, OTCQX: MRMD) announced its Q2 financial results for 2022, reporting a revenue of $33.0 million, a slight increase from $32.6 million in Q2 2021. The company faced challenges with a gross margin of 45%, down from 60% YoY, and a GAAP net income of $1.9 million, decreasing from $7.6 million. Non-GAAP Adjusted EBITDA was $8.9 million, down from $13.9 million, with a margin of 27%. The revised 2022 revenue guidance is $135 million to $140 million, lower than the previous estimate of $145 million to $150 million. MariMed expanded its operational footprint with several acquisitions and product launches.
MariMed, a multi-state cannabis operator (CSE: MRMD, OTCQX: MRMD), has launched a new line of cannabis-infused ice cream in collaboration with Boston's Emack & Bolio’s. This product features vegan and dairy options, debuting two flavors, Cup O’ Coffee Chip and Chocolate Sunny Days, available at Panacea Wellness dispensary in Middleborough, MA. The ice cream is made using MariMed's full spectrum cannabis oil and natural ingredients, aligning with the company's commitment to quality. More flavors and broader distribution are anticipated in the upcoming months.
MariMed, Inc. (CSE: MRMD, OTCQX: MRMD) announced its subsidiary, Kind Therapeutics USA, has received approval to expand its production kitchen in Hagerstown, Maryland. This expansion boosts production capacity to meet rising demand for its branded cannabis products. Currently, their products are available in nearly all of Maryland's 100 dispensaries. With expected increases in demand following potential adult-use cannabis legalization in November, the company aims for GMP certification, promoting health and safety standards. Maryland achieved over $500 million in medical cannabis sales in 2021.
MariMed, a leading multi-state cannabis operator, announced its shares will begin trading on the Canadian Securities Exchange (CSE) under the ticker symbol MRMD on July 12, 2022. This dual listing aims to enhance liquidity and attract a broader range of investors, including institutional and retail, and potentially increase Wall Street analyst coverage. MariMed continues to trade on the OTCQX under the same ticker. The company is dedicated to high-quality cannabis products and operates state-licensed facilities across multiple states.
MariMed, Inc. (OTCQX: MRMD), a leading cannabis operator, announced plans to report its second quarter 2022 financial results on August 8, 2022, after market close. A conference call will be held on August 9, 2022, at 8:00 a.m. EST to discuss the results. Investors may access the call via MariMed's Investor Relations website, with a playback available for 30 days. MariMed focuses on high-quality cannabis products and operates state-licensed facilities, emphasizing excellence in cultivation and product development.
MariMed, Inc. (OTCQX: MRMD) announced the receipt of its final long-form prospectus from the Ontario Securities Commission, positioning the company for a dual listing on the Canadian Securities Exchange (CSE). The anticipated listing under the symbol MRMD is projected to occur in July 2022, pending the completion of customary conditions. CFO Susan Villare stated that this move aims to enhance liquidity and trading volume, making it easier for investors to trade MariMed shares.
MariMed (OTCQX: MRMD) has announced a licensing agreement with East Coast Cannabis Company for the adult-use distribution of its popular Betty’s Eddies full-spectrum fruit chews in Maine. This strategic move aims to expand MariMed’s brand presence in the cannabis market, which is projected to grow to $500 million by 2025. Betty’s Eddies has been a top seller in states where it is available, and this agreement builds on an earlier partnership for medical cannabis distribution. The company plans to introduce more products in the future.
MariMed Inc. (OTCQX: MRMD) announced its "World’s Largest Cannabis Brownie" campaign received two prestigious communications awards for effectiveness in promoting the company and its Bubby’s Baked product line. The 850-pound brownie, infused with 20,000 mg of THC, garnered over five billion consumer impressions, being featured in major media outlets worldwide. The campaign won a Gold "Stevie®" Award and was a finalist for a Public Relations Society of America award. This recognition highlights MariMed’s innovative marketing approach amidst regulatory challenges in the cannabis industry.
MariMed Inc. (OTCQX: MRMD) has been awarded a provisional dispensary license by the Ohio Board of Pharmacy, enabling the development of a medical dispensary in Tiffin, Ohio. This license was secured through Ohio's lottery process, and the company must complete the buildout and pass inspection by February 2023. MariMed plans to expand its operations in Ohio, aiming to maximize its cannabis licenses under state regulations. With over $350 million in medical cannabis sales in 2021 and 260,000 registered patients, Ohio presents significant growth opportunities for MariMed.
MariMed Inc. announced key leadership changes effective May 12, 2022, promoting Jon Levine to Chief Administration Officer (CAO) and appointing Susan Villare as Chief Financial Officer (CFO). Jon Levine, a co-founder and former CFO, will oversee operations, sales, marketing, and external communications as CAO, aiming to execute the company’s strategic growth plan. Susan Villare brings nearly 30 years of finance experience, having previously held senior roles in various organizations. These appointments are expected to enhance MariMed's market position in the multi-state cannabis industry.
FAQ
What is the current stock price of Marimed (MRMD)?
What is the market cap of Marimed (MRMD)?
